UK drug firm Shire recommends takeover by US rival AbbVie

Automatic Inspection Machine - Ampules Shire is known primarily as a maker of drugs to treat rare diseases

Related Stories

British drug firm Shire is recommending a takeover offer from US rival AbbVie after its most recent offer of £53.20 ($91.05) per share.

The board of the UK pharmaceutical company says it will be recommending the offer to shareholders.

The US company began bidding for Shire in May. The deal is an attractive one for AbbVie, as it could dramatically reduce its tax bill.

AbbVie had raised its offer to £51.15 ($87.54) per share last Tuesday.

Under the new offer, Shire shareholders would own approximately 25% of the combined new firm.

Shire, which is based in Basingstoke, Hampshire, said in a statement: "The board of Shire has indicated to AbbVie that it would be willing to recommend an offer at the level of the revised proposal to Shire shareholders, subject to satisfactory resolution of the other terms of the offer."

Shire's shares rose 5.9% to close at £48.70 in London on Friday, valuing the company at £28.7bn. AbbVie's closed at $54.95 (down 0.76%).

More on This Story

Related Stories

The BBC is not responsible for the content of external Internet sites

More Business stories

RSS

Features

  • Polish and British flags alongside British roadsideWar debt

    Does the UK still feel a sense of obligation towards Poles?


  • Alana Saarinen at pianoMum, Dad and Mum

    The girl who has three biological parents


  • Two young Red deer stags practice their rutting in the long grass in Richmond Park, London - 1 September 2014Day in pictures

    The best news photos from around the world in the past 24 hours


  • Islamic State fighters parade in Raqqa, Syria (30 June 2014)Who backs IS?

    Where Islamic State finds support to become a formidable force


From BBC Capital

Programmes

  • Art installationClick Watch

    How one artist is using computer code to turn internet radio into a unique piece of music

BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.